Advertisement

Topics

Latest "Somna Therapeutics LLC" News Stories

00:39 EDT 25th June 2018 | BioPortfolio

Here are the most relevant search results for "Somna Therapeutics LLC" found in our extensive news archives from over 250 global news sources.

More Information about Somna Therapeutics LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Somna Therapeutics LLC for you to read. Along with our medical data and news we also list Somna Therapeutics LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Somna Therapeutics LLC Companies for you to search.

Showing "Somna Therapeutics" News Articles 1–25 of 6,400+

Sunday 24th June 2018

Renova Therapeutics Announces an Abstract to be Presented at the Late-Breaking Scientific ...

In a blinded study, urocortin 2 (UCn2) gene-treated Akita mice showed normalization of fasting blood glucose, HbA1c and glucose tolerance, along with normalization of body Read more...


CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear, unmet needs in the animal health market, focusing on companion animals. We have a lead drug candidate that...

Saturday 23rd June 2018

Week in Review: CITIC Offers $3.6 Billion to Acquire China Biologic

Deals and Financings  CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products, one of China's five largest plasma-based biopharmas; CSL Limited of Australia will pay $102 million to buy 20% of RuiDe Biological. a China plasma company; one year ago it paid $352 million for an 80% stake in RuiDe; Stealth Biotherapeutics, a Boston


CASI, Yiling Wanzhou International Pharma ink contract manufacturing pact for entecavir and cilostazol

CASI Pharmaceuticals, Inc, a biopharmaceutical company dedicated to the development and delivery of high quality, cost─effective pharmaceutical products and innovative therapeutics to patients in the US,

Johnson Fistel Announces Investigations of Veevo Instruments Inc., Insys Therapeutics, Inc. ...

Johnson Fistel, LLP is investigating potential violations of the federal and state securities laws on behalf of former stockholders of Ultratech, Inc. ("Ultratech"). Former Read more...

Friday 22nd June 2018

Nkarta licenses IP from National Univ. of Singapore, St. Jude Children's

Nkarta Therapeutics Inc. licensed exclusive global rights to natural killer (NK) cell engineering technology jointly owned by...

Neon Therapeutics files for IPO

Neon Therapeutics Inc. (immuno-oncology) filed for its initial public offering.

Initial public offering nets $93mm for Magenta Therapeutics

Magenta Therapeutics Inc. (curative stem cell transplantation) netted $93mm through its initial public offering of 6.67mm com...

The Current issue of “The view from here” is concerned with Therapeutics

The topic of this month’s newsletter from Drug Discovery Today is “Therapeutics”

Gemini Therapeutics Names Sandra Rojas-Caro Chief Medical Officer

Sandra Rojas-Caro has been appointed chief medical officer of Cambridge, MA-based Gemini Therapeutics. She was most recently chief medical officer for Aeglea BioTherapeutics. In other moves, Gemini named Claude Knopf to the position of chief business officer and promoted Scott Lauder to chief technology officer. Last fall, Gemini raised $42 million in Series A financing […]

Company Profile for Galectin Therapeutics Inc.

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alco...

STAT Plus: Pharmalittle: E.U. health chief calls Trump freeloading claim ‘fake news’; one drug maker says no to Right to Try

Sarepta Therapeutics says it will not offer pre-approval access under right-to-try legislation or the FDA's expanded access program for any of its Duchenne muscular dystrophy drugs under development.

BriaCell Therapeutics with an update on its Off The Shelf breast cancer treatment reducing drug treatment costs

BriaCell Therapeutics (TSX-V:BCT, OTCMKTS:BCTXF) president & CEO Bill Williams speaks to Proactive about the evolution of the company, why he invested his own funds in BriaCell’s growth, and the development of Bria OTS — the first-ever off-the-shelf treatment for breast cancer. He discussed the group’s funding and growth  plans.

Crescita Therapeutics leverages its unique drug delivery systems and a strong pipeline for growth

Crescita Therapeutics Inc. (TSX:CTX) executive chairman of the Board Dan Chicoine talks to Proactive about the rapid growth of its prescription dermatology lines and how it is leveraging its unique drug delivery systems to support growth of its product lines. He also discussed how the company deals with intense competition in the skincare industry.

vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at ...

TG Therapeutics, Novimmune ink agreement to develop and commercialize novel anti─CD47/anti─CD19 bispecific antibody

TG Therapeutics, Inc and Novimmune SA, announced that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune's novel first─in─class

Checkpoint Therapeutics (CKPT) Presents At The JMP Securities Life Science Conference - Slideshow

Heron Therapeutics (HRTX) Updates On HTX-011 Postoperative Pain Program (Topline Results from Phase 2b Studies) - Slideshow

Scioto Biosciences to Present at Microbiome Movement – Drug Development Summit in Boston

"Bugs as Better Drugs: Leveraging Biofilms for Better Live Bacterial Therapeutics" Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that it will present at the Microbiome Movement – Drug Development Summit on June 22nd at The Seaport Hotel and ...

InVivo Therapeutics announces pricing of $13.2M offering

A public stock offering has been priced by InVivo Therapeutics in hopes of raising $13.2 million in gross proceeds.  -More- 

Discovery of a new vehicle peptide opens drug delivery routes

A new Tokyo Medical and Dental University (TMDU) study identifies promising lead compound for delivery of therapeutically effective peptides In the field of anticancer therapeutics, cationic antimicrobial peptides (AMPs) have gained prominence because of...

Voyager's Parkinson's disease drug nabs FDA RMAT status

Voyager Therapeutics' drug candidate VY-AADC, being developed to treat patients with Parkinson's disease whose motor fluctuat -More- 

Oppenheimer raises Heron Therapeutics' price target 47% on promise of post-op painkiller

Analysts forecast peak sales of US$1bn for the San Diego biotech’s HTX-011 treatment for postoperative pain

Alexo Therapeutics Changes Name to ALX Oncology

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced the change of the Company’s name to ALX Oncology. The new name and logo will differentiate ALX Oncology (ALX) from other companies in the field as the Company advances its clinical programs. “...

APAC Biotech and Diakonos Sign Technology Transfer and Licensing Agreement to Bring New Immunotherapy Technology to India

HOUSTON, June 22, 2018 /PRNewswire/ -- India-Based APAC Biotech and US-Based Diakonos Research sign a first-of-its-kind technology transfer and licensing agreement to bring new immunotherapy technology to India as an advancement of immuno-oncology therapeutics for solid tumors. This new path breaking technology effectively targets and activates the t


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks